Latest News

Quarterly Cashflow and Activities Report (ASX Announcement)

Jul 30th, 2021

Starpharma (ASX: SPL, OTCQX: SPHRY) today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 June 2021.

Read More

Lynda Cheng appointed as non-executive director (ASX Announcement)

Jul 28th, 2021

Melbourne, Australia; 28 July 2021: Starpharma Holdings Limited The Board of Starpharma (ASX: SPL, OTCQX: SPHRY) is pleased to announce the appointment of Ms Lynda Cheng as an independent non-executive director, effective 1 August 2021.   ... Ms Cheng has more than 25 years of experience as a finance executive including more than 15 years at Visy Industries/Pratt... Read More

Starpharma to present DEP® platform at CRS Annual Meeting (ASX Announcement)

Jul 27th, 2021

Melbourne, Australia; 27 July 2021: Starpharma (ASX: SPL, OTCQX: SPHRY) today announces that it has been invited to present at the prestigious Controlled Release Society (CRS) Virtual Annual Meeting. Starpharma will be represented by its VP of Research, Dr David Owen, who will present an overview of the DEP® platform and its benefits as part of the ‘Success Stories from Bench... Read More

Starpharma (ASX:SPL) shows 99.99pc antiviral activity against Delta COVID-19 variant

Jul 27th, 2021

"Starpharma's (SPL) SPL7013 drug has shown a reduction of more than 99.99 per cent against the Delta variant of SARS-CoV-2," The Market Herald reports. Read the full article here.  Read More

In the media

Starpharma (ASX:SPL) shows 99.99pc antiviral activity against Delta COVID-19 variant

Jul 27th, 2021

"Starpharma's (SPL) SPL7013 drug has shown a reduction of more than 99.99 per cent against the Delta variant of SARS-CoV-2," The Market Herald reports. Read the full article here.  Read More

COVID-19: Viraleze Nasal Spray Highly Effective Against Alpha, Beta And Gamma Variants

Jun 19th, 2021

"New data released on June 18 showed that Australia’s Viraleze anti-COVID nasal spray is more than 99.99 per cent effective against three of the four variants of the SARS-CoV-2 virus," as reported by Republic World. Read the full article here.

Read More

Latest Testing Confirms Viraleze Highly Effective Against Alpha, Beta and Gamma COVID Variants

Jun 18th, 2021

News18 reports on Starpharma's latest VIRALEZETM announcement: "New data released today shows that Australia’s Viraleze anti-COVID nasal spray is more than 99.9% effective against three of the four deadliest variants of the SARS-CoV-2 virus." Read the full article here.

Read More

Latest testing confirms Viraleze highly effective against Alpha, Beta and Gamma COVID variants

Jun 18th, 2021

Markets Insider features Starpharma's latest announcement, ..."The results hold significant promise for Viraleze™ – developed by Melbourne-based biopharmaceutical company Starpharma (ASX: SPL) – in the fight against new and emerging variants of SARS-CoV-2, as several countries begin their long-awaited opening of international borders..." Read the full article here

Read More

Shareholder Updates

Shareholder Newsletter

Apr 28th, 2021

The Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) Shareholder Update – April 2021 is now available to view online.

Read More

Shareholder Update October 2020

Oct 20th, 2020

In this issue:

>> Starpharma is expediting the development of the SPL7013 COVID‑19 nasal spray

>> Rapid progress in the DEP® irinotecan phase 2 & preparations underway for clinical combinations

>> DEP® irinotecan in combination with immuno-oncology showed superior performance in colon cancer models

>> VivaGel® BV launched in Central & Eastern Europe and Nordic region

>> Fleurstat BVgel gains expanded TGA approval to include prevention of recurrent Bacterial Vaginosis (BV) indication

>> VivaGel® BV has now been approved in 40 countries with further submissions underway

>> Starpharma awarded $1 million MRFF funding for COVID-19 nasal spray

>> DEP® docetaxel update & patient case study

>> DEP® cabazitaxel update & patient case study

>> Multiple DEP® products showcased at AACR 2020 Annual Meeting

>> New DEP® partnership signed with Chase Sun for anti-infective program

>> AstraZeneca’s AZD0466 trial opens at MD Anderson Cancer Center

>> Starpharma creates slow release soluble DEP® remdesivir

>> DEP® partnering, including Antibody Drug Conjugates

>> DEP® lutetium; impressive efficacy in human prostate cancer model

>> Outlook, Annual Report & ESG Report & recent news 

Read More

Sign up to receive news here